Company news
Dyne Therapeutics, Inc. (NASDAQ:DYN) news
Every Dyne Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NM...
September 3, 2026
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
July 29, 2026
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular...
July 28, 2026
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
July 21, 2026
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dys...
July 20, 2026
Dyne Therapeutics Appoints Barry Greene to Board of Directors
June 22, 2026
Dyne Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
June 19, 2026
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
June 17, 2026
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dys...
June 3, 2026
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular ...
May 26, 2026
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned B...
May 20, 2026
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 11, 2026
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ...
April 27, 2026
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Po...
April 1, 2026
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
March 8, 2026
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
March 8, 2026
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
March 2, 2026
Dyne Therapeutics to Participate in Upcoming Investor Conferences
February 25, 2026
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
February 22, 2026
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen for Myotonic Dystrophy Type 1
January 21, 2026
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
January 20, 2026
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
December 23, 2025
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Ad...
December 11, 2025
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
December 9, 2025
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
December 8, 2025
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
December 8, 2025
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DE...
December 7, 2025
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 5, 2025
Dyne Therapeutics to Present at Upcoming Investor Conferences
November 3, 2025
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleci...
October 6, 2025
Dyne Therapeutics Appoints Brian Posner to its Board of Directors
October 2, 2025
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
September 29, 2025
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
August 4, 2025
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
July 28, 2025
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional...
July 2, 2025
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital
June 30, 2025
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
June 30, 2025
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following ...
June 17, 2025
Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tues...
June 16, 2025
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Co...
June 5, 2025
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 8, 2025
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
April 24, 2025
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
April 15, 2025
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 14, 2025
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
March 20, 2025
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
March 20, 2025
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstra...
March 16, 2025
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum
March 11, 2025
Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
February 27, 2025